References

Antidepressants: Quality prescribing - a guide for improvement
Scottish Government Effective Prescribing & Therapeutics Division
Polypharmacy icon of two pills
  1. Information Services Division. Medicines used in mental health: Years 2009/10 to 2018/19. 2019. URL: https://webarchive.nrscotland.gov.uk/20200214122006/https://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Publications/2019-10-22/2019-10-22-PrescribingMentalHealth-Report.pdf?14530581236 (Accessed 3 June 2024).
  2. Moore M, Yuen H, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: A descriptive study using the general practice research database. BMJ. 2009;339(7727):956.
  3. Kendrick T, Stuart B, Newell C, Geraghty AWA, Moore M. Did NICE guidelines and the quality outcomes framework change GP antidepressant prescribing in England? observational study with time trend analyses 2003-2013. J Affect Disord. 2015;186:171-177.
  4. Middleton DJ, Cameron IM, Reid IC. Continuity and monitoring of antidepressant therapy in a primary care setting. Quality in Primary Care. 2011;19:109-113.
  5. Johnson CF, Williams B, MacGillivray SA, Dougall NJ, Maxwell M. 'Doing the right thing': Factors influencing GP prescribing of antidepressants and prescribed doses. BMC Family Practice. 2017;18(1):72.
  6. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. Lancet. 2012;380(9836):37-43.
  7. Johnson C,F., Dougall N,J., Williams B, Macgillivray S,A., Buchanan A,I., Hassett R,D. Patient factors associated with SSRI dose for depression treatment in general practice: A primary care cross sectional study. BMC Family Practice. 2014;15:210.
  8. Health Improvement Scotland, 2022. Why ask what matters? URL: https://www.whatmatterstoyou.scot/ (Accessed 3 June 2024)
  9. Scottish Government, 2018. Polypharmacy Model of care Group. Polypharmacy Guidance Realistic Prescribing 3rd Edition. URL: https://www.therapeutics.scot.nhs.uk/polypharmacy/ (Accessed 3 June 2024)
  10. Svensson S.A., Hedenrud T.M., Wallerstedt SM. Attitudes and behaviour towards psychotropic drug prescribing in Swedish primary care: A questionnaire study. BMC family practice. 2019;20(1):4.
  11. Malpass A, Kessler D, Sharp D, Shaw A. 'I didn't want her to panic': Unvoiced patient agendas in primary care consultations when consulting about antidepressants. British Journal of General Practice. 2011;61(583):e63-71.
  12. Leydon GM, Rodgers L, Kendrick T. A qualitative study of patient views on discontinuing long-term selective serotonin reuptake inhibitors. Fam Pract. 2007;24(6):570-575.
  13. Maund E, Dewar-Haggart R, Williams S, et al. Barriers and facilitators to discontinuing antidepressant use: A systematic review and thematic synthesis. J Affect Disord. 2019;245:38-62.
  14. Bowers HM, Williams SJ, Geraghty AWA, et al. Helping people discontinue long-term antidepressants: Views of health professionals in UK primary care. BMJ Open. 2019;9(7):e027837.
  15. Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology. 2021;11(pagination):ate of Pubaton: 2021.
  16. Van Leeuwen E, Maund E, Woods C, et al. Health care professional barriers and facilitators to discontinuing antidepressant use: A systematic review and thematic synthesis. Journal of Affective Disorders 2024;356:616-27. URL: https://doi.org/10.1016/j.jad.2024.04.060 (Accessed 24 June 2024)
  17. Johnson CF, Macdonald HJ, Atkinson P, et al. Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. Br J Gen Pract 2012; DOI: https://doi.org/10.3399/bjgp12X658304 (Accessed 27 June 2024)
  18. Taylor DM, Barnes TRE, Young AH, eds. The Maudsley prescribing guidelines in psychiatry. 14th ed. Chichester, UK: Wiley-Blackwell; 2021.
  19. Guy A, Brown M, Lewis S, Horowitz M. The ‘patient voice’: Patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Therapeutic Advances in Psychopharmacology. 2020;10:2045125320967183.
  20. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology Guidelines. J Psychopharmacol. 2015;29(5):459-525.
  21. Saragoussi D, Chollet J, Bineau S, Chalem Y, Milea D. Antidepressant switching patterns in the treatment of major depressive disorder: A general practice research database (GPRD) study. Int J Clin Pract. 2012;66(11):1079-1087.
  22. Van Leeuwen E, van Driel ML, Horowitz MA, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database of Systematic Reviews. 2021;4:013495.
  23. Maund E, Stuart B, Moore M, et al. Managing antidepressant discontinuation: A systematic review. Annals of Family Medicine. 2019;17(1):52-60.
  24. Parish PA. The prescribing of psychotropic drugs in general practice. J R Coll Gen Pract. 1971;21(92 Suppl 4):1-77.
  25. Middleton N, Gunnell D, Whitley E, Dorling D, Frankel S. Secular trends in antidepressant prescribing in the UK, 1975-1998. J Public Health Med. 2001;23(4):262-267.
  26. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.
  27. Hirschfeld RMA. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs. J Clin Psychiatry. 1999;60(5):326-335.
  28. Pilgrim D, Bentall R. The medicalisation of misery: A critical realist analysis of the concept of depression. Journal of Mental Health. 1999;8(3):261-274.
  29. Dowrick C, Frances A. Medicalising unhappiness: New classification of depression risks more patients being put on drug treatment from which they will not benefit. BMJ. 2013;347:f7140.
  30. Henderson C, Robinson E, Evans-Lacko S, et al. Public knowledge, attitudes, social distance and reported contact regarding people with mental illness 2009-2015. Acta Psychiatr Scand. 2016;134(Suppl 446):23-33.
  31. Joint Formulary Committee. British national formulary. London: BMJ Group and Pharmaceutical Press; 2020.
  32. Lee KC, Feldman MD, Finley PR. Beyond depression: Evaluation of newer indications and off-label uses for SSRIs. Formulary. 2002;37(6):312-319.
  33. Finnerup N.B., Attal N., Haroutounian S., et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. The Lancet Neurology. 2015;14(2):162-173.
  34. Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995–2007: A longitudinal population database analysis. Br J Gen Pract. 2011;61(590):e565-e572.
  35. Sinclair JE, Aucott LS, Lawton K, Reid IC, Cameron IC. The monitoring of long term prescriptions if antidepressants: Observational study in a primary care setting. Fam Pract. 2014;31(4):419-426.
  36. National Institute for Health and Care Excellence. National Guideline 222: Depression in adults: treatment and management. June 2022. URL: https://www.nice.org.uk/guidance/ng222 (Accessed 3 June 2024).
  37. National Institute for Health and Care Excellence. NICE Clinical Guideline 113: Generalised anxiety disorder and panic disorder in adults: Management. Updated June 2020. URL: www.nice.org.uk/guidance/cg113 (Accessed 3 June 2024).
  38. National Institute for Health and Care Excellence. NICE National Guideline 116: Post-traumatic stress disorder. 2018. URL: https://www.nice.org.uk/guidance/NG116 (Accessed 3 June 2024).
  39. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. European Archives of Psychiatry & Clinical Neuroscience. 2005;255(6):387-400.
  40. Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: A systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601-609.
  41. Furukawa T.A., Salanti G., Cowen P.J., Leucht S., Cipriani A. No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: Systematic review. Acta Psychiatr Scand. 2020;141(5):401-409.
  42. Johnson CF, Maxwell M, Williams B, et al. Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis. BMJ Medicine 2022;1(1):e000017. doi: 10.1136/bmjmed-2021-000017
  43. Seppala L.J., Wermelink A.M.A.T., de Vries M., et al. Fall-risk-increasing drugs: A systematic review and meta-analysis: II. psychotropics. Journal of the American Medical Directors Association. 2018;19(4):371.e11-371.e17.
  44. Dold M., Bartova L., Rupprecht R., Kasper S. Dose escalation of antidepressants in unipolar depression: A meta-analysis of double-blind, randomized controlled trials. Psychother Psychosom. 2017;86(5):283-291.
  45. Ruhe H, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: Systematic review. Br J Psychiatry. 2006;189:309-316.
  46. Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogues in Clinical Neuroscience. 2005;7(3):249-262.
  47. Arterburn D., Sofer T., Boudreau D.M., et al. Long-term weight change after initiating second-generation antidepressants. Journal of Clinical Medicine. 2016;5(4) (pagination):Arte Number: 48. Date of Publication: 13 Ar 2016.
  48. Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: A systematic review. Obesity Reviews. 2019;20(12):1680-1690.
  49. Bazire S. Psychotropic drug directory. Lloyd-Reinhold Publications; 2018.
  50. National Institute for Health and Care Excellence. NICE CG 173: Neuropathic pain – pharmacological management: The pharmacological management of neuropathic pain in adults in non-specialist Accessed 3 June 2024).
  51. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long qt syndrome: A comprehensive review. The Scientific World Journal. 2012;2012.
  52. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. British Journal of Psychiatry. 2002;180:396-404.
  53. Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: Review of comparisons to placebo and standard antidepressants using dissimilar methods. Human Psychopharmacology. 2009;24(3):177-190.
  54. Bymaster F.P., Lee T.C., Knadler M.P., Detke M.J., Iyengar S. The dual transporter inhibitor duloxetine: A review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-1493.
  55. Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol. 1996;16(3 SUPPL. 3):21S-28S.
  56. Stein M.B., Pollack M.H., Bystritsky A., Kelsey J.E., Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacology (Berl). 2005;177(3):280-288.
  57. WHO. Definition and general considerations of defined daily doses 2022 http://www.whocc.no/ddd/definition_and_general_considera/ (Accessed 3 June 2024).
  58. Department of Health and Social Care, Good for you, good for us, good for everybody, 2021, URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1019475/good-for-you-good-for-us-good-for-everybody.pdf (Accessed 3 June 2024).
  59. Royal Pharmaceutical Society, Sustainability Policy, 2021, URL:  https://www.rpharms.com/recognition/all-our-campaigns/policy-a-z/pharmacys-role-in-climate-action-and-sustainable-healthcare (Accessed 3 June 2024).
  60. Royal College of General Practitioners Council Motion, Sustainable development, climate change and green issues, 2019, URL: https://www.rcgp.org.uk/policy/rcgp-policy-areas/climate-change-sustainable-development-and-health (Accessed 3 June 2024).
  61. SEPA. Pharmaceuticals in waste water. URL: https://informatics.sepa.org.uk/EnvironmentalPharmaceuticals/ (Accessed 3 June 2024)
  62. Sustainable Markets Initiative Health Systems Task Force, in collaboration with BCG, Decarbonising Patient Care Pathways, November 2022. URL: smi-hstf-pcp-whitepaper.pdf (storyblok.com) (Accessed 24 June 2024)
  63. Adarsh Singh, Duduku Saidulu, Ashok Kumar Gupta, Vijay Kubsad. Occurrence and fate of antidepressants in the aquatic environment: Insights into toxicological effects on the aquatic life, analytical methods, and removal techniques, Journal of Environmental Chemical Engineering, Volume 10, Issue 6, 2022, 109012, ISSN 2213-3437, https://doi.org/10.1016/j.jece.2022.109012 (Accessed 3 June 2024)
  64. Janusinfo Region Stockholm, Pharmaceuticals and Environment, URL: https://janusinfo.se/beslutsstod/lakemedelochmiljo/pharmaceuticalsandenvironment.4.7b57ecc216251fae47487d9a.html (Accessed 14 June 2024)
  65. Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database of Systematic Reviews. 2013(9):CD004366.
  66. McGrath M, Duncan F, Dotsikas K, et al. Effectiveness of community interventions for protecting and promoting the mental health of working-age adults experiencing financial uncertainty: A systematic review. J Epidemiol Community Health. 2021;75:665-673.
  67. Coventry P.A., Brown J.E., Pervin J., et al. Nature-based outdoor activities for mental and physical health: Systematic review and meta-analysis. SSM - Population Health. 2021;16(pagination):Arte Number: 100934. Date of Publication: December 2021.
  68. Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Duration of major depressive episodes in the general population: Results from the netherlands mental health survey and incidence study (NEMESIS). British Journal of Psychiatry. 2002;181:208-213.
  69. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British association for psychopharmacology. Journal of Psychopharmacology. 2014;28(5):403-439.
  70. National Institute for Health and Care Excellence. NICE National Guideline Low back pain and sciatica in over 16s: Assessment and management (update 2020). 2016. URL: https://www.nice.org.uk/guidance/ng59 (Accessed 3 June 2024).
  71. National Institute for Health and Care Excellence. NICE National Guideline 193: Chronic pain (primary and secondary) in over 16s: Assessment of all chronic pain and management of chronic pain. 2021.
  72. Scottish Intercollegiate Guidelines Network (SIGN), 2019. Management of Chronic Pain SIGN 136. https://www.sign.ac.uk/media/2097/sign136_2019.pdf (Accessed 3 June 2024).
  73. Szegedi A, Jansen WT, van Willigenburg APP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353.
  74. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US food and drug administration. BMJ. 2009;339:b2880.
  75. Dougall N, Stark C, Agnew T, Henderson R, Maxwell M, Lambert P. An analysis of suicide trends in scotland 1950-2014: Comparison with England & Wales. BMC Public Health. 2017;17(1):970.
  76. National Institute for Health and Care Excellence. Bipolar disorder in adults (QS95). 2015.
  77. Houston K, Haw C, Townsend E, Hawton K. General practitioner contacts with patients before and after deliberate self harm. British Journal of General Practice. 2003;53(490):365-370.
  78. Arroll B, Chin W, Martis W, et al. Antidepressants for treatment of depression in primary care: A systematic review and meta-analysis. Journal of Primary Health Care. 2016;8(4):325-334.
  79. Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews. 2009(3):007954.
  80. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database of Systematic Reviews. 2008:(1)-2008 Jan 23.
  81. Leucht S., Hierl S., Kissling W., Dold M., Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: Review of meta-analyses. British Journal of Psychiatry. 2012;200(2):97-106.
  82. Papakostas GI. Limitations of contemporary antidepressants: Tolerability. J Clin Psychiatry. 2007;68(Suppl 10):11-17.
  83. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):37-41.
  84. Nutt DJ. Tolerability and safety aspects of mirtazapine. Human Psychopharmacology. 2002;17(SUPPL. 1):S37-S41.
  85. Alonso-Pedrero L., Bes-Rastrollo M., Marti A. Effects of antidepressant and antipsychotic use on weight gain: A systematic review. Obesity Reviews. 2019;20(12):1680-1690.
  86. Johnson CF, Liddell K, Guerri C, Findlay P, Thom A. Medicines reconciliation at the community mental health team-general practice interface: Quality improvement study. BJPsych Bull. 2020;44(1):12-18.
  87. Elliott R, Camacho E, Campbell F, et al. Prevalence and economic burden of medication errors in the NHS in England: Rapid evidence synthesis and economic analysis of the prevalence and burden of medication error in the UK. 2018:1-174.
  88. Mekonnen AB, McLachlan AJ, Brien JE. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: A systematic review and meta-analysis. BMJ Open. 2016;6(2):e010003.
  89. National Institute for Health and Care Excellence. NICE CG 31: Obsessive-compulsive disorder and body dysmorphic disorder: Treatment (update April 2020); 2005. URL: https://www.nice.org.uk/guidance/cg31 (Accessed 3 June 2024).
  90. National Institute for Health and Care Excellence. NICE CG 185: Bipolar disorder: Assessment and management (update Dec 2023). 2014. URL: https://www.nice.org.uk/guidance/cg185 (Accessed 3 June 2024).
  91. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the british association for psychopharmacology. Journal of Psychopharmacology. 2005;19(6):567-596.
  92. Jiang H, Chen H, Hu X, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: A systematic review and meta-analysis. Clinical Gastroenterology & Hepatology. 2015;13(1):42-50.e3.
  93. Zhang Y, Souverein PC, Gardarsdottir H, van den Ham HA, Maitland-van der Zee A, de Boer A. Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. Br J Clin Pharmacol. 2020;86(6):1150-1164.
  94. Stockley's drug interactions. URL: https://about.medicinescomplete.com/publication/stockleys-interactions-checker/ Updated 2021. (Accessed 3 June 2024).
  95. Wang M, Zeraatkar D, Obeda M, et al. Drug–drug interactions with warfarin: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4051-4100.
  96. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: A cross sectional study of electronic health records. BMJ. 2013;346(7894):f288.
  97. van Noord C, Straus SM, Sturkenboom MC, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol. 2009;29(1):9-15.
  98. Medicines and Healthcare products Regulatory Agency. Citalopram and escitalopram: QT interval prolongation—new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings, URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON137769 Updated 2011. (Accessed 3 June 2024).
  99. NHS Greater Glasgow and Clyde Medicines Information Service. Medicines update extra: Drug induced QT prolongation. 2018(8).
  100. Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database of Systematic Reviews. 2002(4):003944.
  101. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577-585.
  102. Banerjee S., Hellier J., Dewey M., et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): A randomised, multicentre, double-blind, placebo-controlled trial. The Lancet. 2011;378(9789):403-411.
  103. National Collaborating Centre for Mental Health. Dementia: Supporting people with dementia and their carers in health and social care. clinical guideline 42. Great Britain: Alden Press; 2007:392.
  104. Sultzer DL, Gray KF, Gunay I, Wheatley MV, Mahler ME. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc. 2001;49(10):1294-1300.
  105. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews. 2011:(2)-2011.
  106. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. Modified Anticholinergic Risk Scale (mARS) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-13. URL: https://www.derbyshiremedicinesmanagement.nhs.uk/assets/Clinical_Guidelines/Formulary_by_BNF_chapter_prescribing_guidelines/BNF_chapter_4/Modified_anticholinergic_risk_scale.pdf (Accessed 14 June 2024)
  107. Dell'osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. European Psychiatry: the Journal of the Association of European Psychiatrists. 2013;28(1):7-20.
  108. Ashton H. Toxicity and adverse consequences of benzodiazepine use. Psychiatric Annals. 1995;25(3):158-165.
  109. Kripke DF. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry. 2007;7:42.
  110. Otto MW, Bruce SE, Deckersbach T. Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: Issues in the treatment of a patient in need. J Clin Psychiatry. 2005;66(Suppl 2):34-38.
  111. Kessler DS, MacNeill SJ, Tallon D, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: Phase III randomised placebo controlled trial (MIR). BMJ (online). 2018;363.
  112. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011;168(7):689-701.
  113. Scottish Government, Chief Medical Officer, National Guidance for monitoring lithium, March 2019. URL: https://www.publications.scot.nhs.uk/files/cmo-2019-04.pdf (Accessed 14 June 2024)
  114. Mitchell A.J., Delaffon V., Vancampfort D., Correll C.U., De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychol Med. 2012;42(1):125-147.
  115. Kirkham E, Skinner J, Anderson T, Bazire S, Twigg MJ, Desborough JA. One lithium level >1.0 mmol/L causes an acute decline in eGFR: Findings from a retrospective analysis of a monitoring database. BMJ Open. 2014;4(11):e006020.
  116. Perry BI, Holt RIG, Chew-Graham CA, Tiffin E, French P, Pratt P, Byrne P, Shiers DE. 2023 update(with acknowledgement to the late Helen Lester for her contribution to the original 2012 version) Positive Cardiometabolic Health Resource: an intervention framework for patients with psychosis and schizophrenia. 2023 update. Royal College of Psychiatrists, London. URL: https://www.rcpsych.ac.uk/docs/default-source/improving-care/ccqi/national-clinical-audits/ncap-library/eip-2024/ncap-lester-tool-intervention-framework.pdf?sfvrsn=21e45dbd_17 (Accessed 3 June 2024).
  117. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews. 2013:(5)-2013 May 31.
  118. Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020;212(7):329-334.
  119. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469-476.
  120. Sorensen A., Ruhe H.G., Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review. Mol Psychiatry. 2021(pagination):Date of Publication: 2021.
  121. Donoghue J, Tylee A, Wildgust H. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. BMJ. 1996;313(7061):861-862.
  122. Donoghue J. Sub-optimal use of tricyclic antidepressants in primary care: Editorial. Acta Psychiatr Scand. 1998;98(6):429-431.
  123. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. Washington DC: American Psychiatric Association; 2010.
  124. Kennedy S.H., Lam R.W., McIntyre R.S., et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. pharmacological treatments. Canadian Journal of Psychiatry. 2016;61(9):540-560.
  125. Rix S, Paykel ES, Lelliott P, et al. Impact of a national campaign on GP education: An evaluation of the defeat depression campaign. British Journal of General Practice. 1999;49(439):99-102.
  126. Malhi G.S., Bassett D., Boyce P., et al. Royal australian and new zealand college of psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087-1206.
  127. Busfield J. 'A pill for every ill': Explaining the expansion in medicine use. Soc Sci Med. 2010;70(6):934-941.
  128. Dohnhammar U., Reeve J., Walley T. Patients' expectations of medicines--a review and qualitative synthesis. Health expectations: an international journal of public participation in health care and health policy. 2016;19(2):179-193.
  129. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-analysis. Arch Gen Psychiatry. 2006;63(11):1217-1223.
  130. Godman B, Kurdi A, McCabe H, et al. Ongoing initiatives within the scottish national health service to affect the prescribing of selective serotonin reuptake inhibitors and their influence. J Comp Eff Res. 2019;8(7):535-547.
  131. Thase ME, Nierenberg AA, Vrijland P, Van Oers HJJ, Schutte A-, Simmons JH. Remission with mirtazapine and selective serotonin reuptake inhibitors: A meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010;25(4):189-198.
  132. Marshe, V.S., Islam, F., Maciukiewicz, M., Bousman, C., Eyre, H.A., Lavretsky, H., Mulsant, B.H., Reynolds III, C.F., Lenze, E.J. and Müller, D.J., 2020. Pharmacogenetic implications for antidepressant pharmacotherapy in late-life depression: a systematic review of the literature for response, pharmacokinetics and adverse drug reactions. The American Journal of Geriatric Psychiatry, 28(6), pp.609-629.
  133. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant withdrawal and rebound phenomena. Deutsches Arzteblatt International. 2019;116(20):355-361.
  134. Jauhar S, Hayes J. The war on antidepressants: What we can, and can't conclude, from the systematic review of antidepressant withdrawal effects by davies and read. Addict Behav. 2019;97:122-125.
  135. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?. Addict Behav. 2019;97:111-121.
  136. Henssler J, Schmidt Y, Schmidt U, et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry 2024;11(7):526-35. doi: https://doi.org/10.1016/S2215-0366(24)00133-0
  137. Lewis G, Marston L, Duffy L, et al. Maintenance or discontinuation of antidepressants in primary care. N Engl J Med. 2021;385(14):1257-1267.
  138. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348:g1626
  139. Isbister G.K., Buckley N.A., Whyte IM. Serotonin toxicity: A practical approach to diagnosis and treatment. Med J Aust 2007;187(6):361-365
  140. Haddad PM. Antidepressant discontinuation syndromes: Clinical relevance, prevention and management. Drug Safety 2001;24(3):183-197
  141. Cosci F. Withdrawal symptoms after discontinuation of a noradrenergic and specific serotonergic antidepressant: A case report and review of the literature. Personalized Medicines in Psychiatry 2017;1-2:81-8
  142. Otani K., Tanaka O., Kaneko S., Ishida M., Yasui N., Fukushima Y. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 1994;9(2):131-133
  143. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000 Jan;85(1):11-28. doi: 10.1016/s0163-7258(99)00048-0. PMID: 10674711.
  144. Electronic Medicines Compendium. Duloxetine. URL: https://www.medicines.org.uk/emc/search?q=duloxetine (Accessed 3 June 2024).
  145. Benazzi F. Fluoxetine for serotonin reuptake inhibitor discontinuation syndrome. Journal of Psychiatry & Neuroscience. 1998;23(4):241-242.
  146. Luckhaus C, Jacob C. Venlafaxine withdrawal syndrome not prevented by maprotiline, but resolved by sertraline. International Journal of Neuropsychopharmacology. 2001;4(1):43-44.
  147. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th Edition ed. Chichester: Wiley Blackwell 2015.
  148. Olver JS, Burrows GD, Norman TR. The treatment of depression with different formulations of venlafaxine: A comparative analysis. Human Psychopharmacology 2004;19(1):9-16.
  149. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. Journal of Clinical Psychopharmacology 1996;16(5):356-62. doi: 10.1097/00004714-199610000-00003
  150. Lane R, Baldwin D, Preskorn S. The SSRIs: advantages, disadvantages and differences. Journal of Psychopharmacology 1995;9(Suppl 2):163-78.
  151. Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: A review of the clinical evidence and the possible mechanisms involved. Frontiers in Pharmacology 2013;4 APR (no pagination)
  152. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet. Psychiatry 2019;6(6):538-546.
  153. Ruhe H.G., Horikx A., van Avendonk M.J.P., et al. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psych 2019;6(7):561-562.
  154. Selvaraj S., Jauhar S., Baldwin D.S., et al. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psych 2019;6(7):560-561.
  155. Moore M, Byng R, Stuart B, Harris T, Kendrick T. 'Watchful waiting' or 'active monitoring' in depression management in primary care: Exploring the recalled content of general practitioner consultations. J Affect Disord. 2013;145(1):120-125.
  156. Silvercloud, ‘How to assess for client suitability for online CBT programmes’, 2014. URL: https://www.silvercloudhealth.com/hubfs/Collaterals/Ebooks/Ebook_client_suitability.pdf (Accessed 3 June 2024)